# DESCRIPTION

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND OF THE INVENTION

- motivate receptor mediated targeted drug delivery
- discuss limitations of current oral drug delivery systems

## SUMMARY OF THE INVENTION

- describe receptor-targeted nanoparticles

## DETAILED DESCRIPTION OF THE INVENTION

- introduce R-targeted nanoparticles

### I. Definitions

- define treating and preventing
- define bioactive agent and active agent
- define sufficient and effective
- define biocompatible and pharmaceutically acceptable

### II. Receptor-Targeted Nanoparticles

- introduce receptor-targeted nanoparticles
- describe particle core composition
- detail polymeric particle core formation
- list hydrophilic and hydrophobic polymers
- describe amphiphilic polymer and lipid components
- detail lipid particle core formation
- describe lipid micelles and liposomes
- introduce receptor-targeted nanoparticles
- describe solid lipid particles
- list suitable neutral and anionic lipids
- list suitable cationic lipids
- describe inorganic particles
- describe hybrid particles
- describe transport mediating receptors
- describe FcRn receptor and its interaction with IgGs
- describe additional targeting moieties
- define FcRn binding moiety
- describe FcRn binding moiety properties
- discuss non-FcRn receptor binding moieties
- describe nanoparticulate formulation targeting
- list therapeutic, prophylactic, and diagnostic agents
- specify diseases and conditions treatable with nanoparticles
- introduce receptor-targeted nanoparticles
- list anticancer active agents
- describe NP formulation for oral administration
- explain targeting of receptors for transcytosis
- discuss loading range for agents within particles
- describe NP formulation for mucosal vaccination
- explain ability of NPs to enter systemic circulation
- list therapeutic agents for various conditions
- describe insulin and insulin analogs for diabetes treatment

### III. Methods of Making R-targeted Nanoparticles

- introduce methods of making nanoparticles
- describe polymeric particle core formation methods
- detail phase separation encapsulation techniques
- outline phase inversion nanoencapsulation method
- describe lipid particle core formation methods
- detail high pressure homogenization methods
- outline solvent evaporation and diffusion methods
- describe inorganic particle core formation methods
- detail physical and chemical preparation methods
- summarize stabilization and microfluidics methods

### IV. Compositions and Formulations of R-Targeted Nanoparticles

- describe enteral formulations
- list suitable dosage forms for enteral administration
- define pharmaceutically acceptable carriers
- describe delayed release dosage formulations
- list suitable coating materials
- describe optional pharmaceutically acceptable excipients
- explain role of diluents, binders, lubricants, disintegrants, and stabilizers
- describe extended release dosage forms
- explain preparation of extended release tablets
- describe delayed release dosage units

### V. Methods of Using R-targeted Nanoparticles and Compositions and Formulations Thereof

- introduce nanoparticle-based therapeutics
- limitations of parenteral administration
- motivate oral administration
- describe nanoparticulate formulation
- summarize receptor-mediated transport
- list various embodiments of nanoparticle formulation
- outline dosage regimens and administration

## EXAMPLES

- present multiple examples of Fc-targeted nanoparticles

### Example 1

- demonstrate FcRn expression in wild-type mice

### Example 2

- prepare Fc-targeted nanoparticles

### Example 3

- study in vitro transepithelial transport of Fc-targeted nanoparticles

### Example 4

- prepare radiolabeled Fc-targeted nanoparticles
- study in vivo absorption and biodistribution of Fc-targeted nanoparticles

### Example 5

- prepare insulin-loaded Fc-targeted nanoparticles
- study oral insulin delivery to wild-type mice using Fc-targeted nanoparticles

### Example 6

- test FcRn role in NP transport

### Example 7

- evaluate dose dependency

